Australia markets closed

Viridian Therapeutics, Inc. (VRDN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
15.40+0.82 (+5.62%)
At close: 04:00PM EDT
15.43 +0.03 (+0.19%)
After hours: 07:10PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 930.53M
Enterprise value 680.73M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.08k
Price/book (mrq)3.95
Enterprise value/revenue 2.17k
Enterprise value/EBITDA -2.89

Trading information

Stock price history

Beta (5Y monthly) 1.10
52-week change 3-42.80%
S&P500 52-week change 322.38%
52-week high 328.35
52-week low 310.93
50-day moving average 316.81
200-day moving average 317.46

Share statistics

Avg vol (3-month) 3906.33k
Avg vol (10-day) 3895.36k
Shares outstanding 563.82M
Implied shares outstanding 663.82M
Float 848.19M
% held by insiders 11.00%
% held by institutions 199.78%
Shares short (15 Apr 2024) 49.73M
Short ratio (15 Apr 2024) 49.72
Short % of float (15 Apr 2024) 417.90%
Short % of shares outstanding (15 Apr 2024) 415.25%
Shares short (prior month 15 Mar 2024) 47.62M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 313 Nov 2020
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 313 Nov 2020

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-99,275.00%

Management effectiveness

Return on assets (ttm)-34.37%
Return on equity (ttm)-56.80%

Income statement

Revenue (ttm)314k
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)-31.40%
Gross profit (ttm)N/A
EBITDA -253.93M
Net income avi to common (ttm)-237.73M
Diluted EPS (ttm)-5.31
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)477.37M
Total cash per share (mrq)7.61
Total debt (mrq)22.04M
Total debt/equity (mrq)4.99%
Current ratio (mrq)18.26
Book value per share (mrq)4.36

Cash flow statement

Operating cash flow (ttm)-184.17M
Levered free cash flow (ttm)-102.82M